AskBio Inc. has announced the advancement of its investigational gene therapy, ametefgene parvec (AB-1005), for Parkinson’s disease (PD) and multiple system atrophy-parkinsonian type (MSA-P) following the submission of an FDA Investigational New Drug Application (IND) amendment. This development allows the company to utilize its newly established, high-efficiency manufacturing process at its Viralgen facility, which is designed to produce a high-purity product necessary for the ongoing REGENERATE-PD Phase II clinical trial. The trial has already initiated participant enrollment across multiple countries, including Germany, Poland, and the United States.

The significance of this advancement lies in the innovative manufacturing technology that underpins the production of ametefgene parvec. This technology not only meets stringent regulatory standards but also enhances the scalability and efficiency of gene therapy production. The therapy utilizes an adeno-associated viral vector to deliver the human glial cell line-derived neurotrophic factor (GDNF) transgene, which has shown promise in promoting the survival of dopaminergic neurons—critical for addressing the neurodegenerative aspects of PD. Given that PD affects over 10 million individuals globally, the urgency for effective therapies is paramount, especially since current treatment options are limited in their ability to manage symptoms holistically.

The takeaway from this development is its potential to shift the paradigm in neurodegenerative disease research and therapy. By demonstrating a viable manufacturing process for gene therapies, AskBio may accelerate timelines for drug development in similar conditions, paving the way for more efficient clinical trials and potentially transformative treatments. This could lead to a broader acceptance of gene therapies in clinical settings, particularly for diseases that currently lack effective treatment options.

Source: globenewswire.com